Proton Pump Inhibitors and Risk of Community-acquired Pneumonia
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine whether proton pump inhibitors (PPIs), a medication
used to treat gastric conditions, increase the risk of hospitalization for community-acquired
pneumonia (HCAP).
The investigators will carry out separate population-based cohort studies using
administrative health databases in eight jurisdictions in Canada, the US, and the UK. Cohort
entry will be defined by the initiation of an oral non-steroidal anti-inflammatory drug, with
follow-up until hospitalization for pneumonia or end of follow-up (6 months). The results
from the separate sites will be combined using a statistical approach called meta-analysis to
provide an overall assessment of the risk of HCAP with PPIs.
Details
Lead Sponsor:
Canadian Network for Observational Drug Effect Studies, CNODES
Collaborators:
Canadian Institutes of Health Research (CIHR) Drug Safety and Effectiveness Network, Canada